Crossmark

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis

Crossref DOI link: https://doi.org/10.1007/s12325-020-01521-9

Published Online: 2020-10-16

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hungria, Vania https://orcid.org/0000-0002-4327-1957
Martínez-Baños, Deborah M.

Mateos, María-Victoria

Dimopoulos, Meletios A.

Cavo, Michele

Heeg, Bart

Garcia, Andrea

Lam, Annette

Machnicki, Gerardo

He, Jianming

Fernandez, Mariana
Funding

Funding for this research was provided by:

Janssen Research and Development

Janssen-Cilag

Janssen Pharmaceuticals
License Information

Text and Data Mining valid from 2020-10-16

Version of Record valid from 2020-10-16
More Information

Article History

Received: 10 August 2020

Accepted: 30 September 2020

First Online: 16 October 2020

Document is current

Any future updates will be listed below